Patents Assigned to Genentech
  • Publication number: 20100273257
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: January 15, 2009
    Publication date: October 28, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, Anan Chuntharapai, Austin Gurney, Kyung Jin Kim, William I. Wood
  • Patent number: 7820161
    Abstract: Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 26, 2010
    Assignees: Biogen Idec, Inc., Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Patent number: 7820806
    Abstract: Methods for producing membrane-spanning polypeptides in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents, as well as use of promoters and expression vectors for expressing high yields of membrane-spanning polypeptides in bacterial cells. Mutated promoters provide tight control of membrane-spanning polypeptides in bacterial cell hosts.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: October 26, 2010
    Assignee: Genentech, Inc.
    Inventors: James A. Ernst, Daniel Yansura, Hok Seon Kim
  • Publication number: 20100267033
    Abstract: The invention provides methods and compositions useful for detecting autoimmune disorders.
    Type: Application
    Filed: March 30, 2010
    Publication date: October 21, 2010
    Applicant: Genentech, Inc.
    Inventors: Alexander Abbas, Barmak Modrek, Michael J. Townsend
  • Publication number: 20100266593
    Abstract: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.
    Type: Application
    Filed: June 29, 2010
    Publication date: October 21, 2010
    Applicant: Genentech, Inc.
    Inventors: James A. Ernst, Paul Polakis, Bonnee Rubinfeld, Venita I. DeAlmeida
  • Publication number: 20100267050
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: April 23, 2010
    Publication date: October 21, 2010
    Applicant: Genentech, Inc.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • Publication number: 20100266698
    Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant.
    Type: Application
    Filed: June 28, 2010
    Publication date: October 21, 2010
    Applicant: GENENTECH, INC.
    Inventors: Ellen H. Filvaroff, Franklin W. Okumu
  • Patent number: 7816369
    Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: October 19, 2010
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Judith Boyd, legal representative, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. MacKinnon
  • Publication number: 20100261888
    Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 14, 2010
    Applicant: Genentech, Inc.
    Inventors: Michelle D. Butler, Jeffrey L. Cleland, David W. Kahn, Shelly Pizarro, Charles H. Schmelzer, Marjorie E. Winkler
  • Publication number: 20100260782
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: March 23, 2010
    Publication date: October 14, 2010
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Patent number: 7812133
    Abstract: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc
    Inventor: Flavius Martin
  • Patent number: 7811777
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech Inc.
    Inventors: Frederic J. de Sauvage, David A. Carpenter
  • Patent number: 7811785
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Patent number: 7811773
    Abstract: The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc.
    Inventor: Peter Ralph
  • Patent number: 7811984
    Abstract: The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer Le Couter
  • Publication number: 20100255010
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 7, 2010
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • Publication number: 20100255515
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 7, 2010
    Applicant: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
  • Publication number: 20100256356
    Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 7, 2010
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Steven Armen Boyd, Jason De Meese, Kin Chiu Fong, John J. Gaudino, Tomas Kaplan, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian, Frederick Cohen, Wendy B. Young
  • Patent number: 7807153
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: October 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Patent number: RE41888
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 26, 2010
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood